Jazz Pharmaceuticals (JAZZ) Misses Q1 EPS by 313c; offers guidance
Tweet
Share
E-mail
Get Alerts JAZZ Hot Sheet
Price: $241.46 +0.30%
Revenue Growth %: +7.1%
Financial Fact:
Total operating expenses: 237.93M
Today's EPS Names:
MLKN, KBH, WOR, More
Revenue Growth %: +7.1%
Financial Fact:
Total operating expenses: 237.93M
Today's EPS Names:
MLKN, KBH, WOR, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q1 EPS of $1.68, $3.13 worse than the analyst estimate of $4.81. Revenue for the quarter came in at $897.84 million versus the consensus estimate of $983.86 million.
GUIDANCE:
Jazz Pharmaceuticals sees FY2025 EPS of $4.00-$5.60, versus the consensus of $23.23. Jazz Pharmaceuticals sees FY2025 revenue of $4.15-4.4 billion, versus the consensus of $4.29 billion.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Deutsche Bank Upgrades Danone SA (BN:FP) (DANOY) to Hold
- Kepler Cheuvreux Downgrades Landsec (LAND:LN) to Hold
- Kotak Starts INDO-MIM Ltd (INDOMIM:IN) at Reduce (3)
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
